Central Surgical Association

CSA Home CSA Home Past & Future Meetings Past & Future Meetings

Back to 2026 Abstracts


Does Ineffective Esophageal Motility on Manometry Determine Outcomes After PEH Repair?
Ayesha Siddiq*, Nicholas Catanzaro, Nicolette Winder, Hamza N. Chatha, Patrick Wieland, Saher Z. Khan, Samuel Zolin, Jeffrey Marks, Joshua Lyons, Leena Khaitan
General Surgery, University Hospitals Cleveland - Case Western Reserve University School of Medicine, Cleveland, OH

Introduction
Although the utility of preoperative esophageal manometry prior to paraesophageal hernia repair (PEHR) is controversial, those with ineffective esophageal motility (IEM) may benefit. Whether IEM independently predicts outcomes post-operatively remains unclear. We aim to evaluate the association between IEM and postoperative outcomes after PEHR.
Methods
Utilizing our institutional database, we identified adult patients who had elective minimally invasive PEHR (2016-2023). Patients with prior PEHR, missing preoperative esophageal manometry or insufficient follow-up data were excluded. The primary exposure was preoperative IEM. The primary outcome was documented radiographic or endoscopic hernia recurrence; secondary was postoperative symptoms.
Unadjusted comparisons used t-tests, chi-square, or Fisher's tests. Multivariable logistic regression evaluated association between IEM and outcomes, adjusting for age, sex, BMI, ASA, operative approach, and fundoplication type.
Results
508 patients met inclusion criteria, 88 (17.32%) had preoperative IEM. Baseline characteristics are shown in table 1. IEM group had a significantly lower BMI (28.26 ± 5.18 vs 30.61± 5.52) and were more likely to undergo fundoplication (78.16% vs 66.34%), particularly Toupet (56.98% vs 23.00%) or Dor (11.63% vs 2.18%).
Unadjusted analyses showed no significant differences in outcomes between groups. On adjusted multivariable analysis, preoperative IEM was not independently associated with hernia recurrence (OR-1.534, 95% CI 0.80-2.95, p=0.200) or redo surgery (OR-1.47, 95% CI 0.45-4.85, p=0.526), while increasing age was associated with higher odds of recurrence (OR-1.02, 95% CI 1.00-1.05, p=0.035).
Persistent dysphagia (>30 days postoperatively) was trended higher in the IEM group, and were more likely to have a procedure for management (table 2).

Conclusion
This study does not demonstrate an association between IEM on preoperative manometry and postoperative recurrence. However, those with IEM are more likely to have persistent dysphagia and may require endoscopic management. This motility finding can be helpful in managing expectations and outcomes following PEHR.
Baseline patient and operative characteristics stratified by preoperative ineffective esophageal motility (IEM)
CharacteristicOverall (N =508)No IEM (N =420)IEM (N = 88)p-value
Age, years59.06 ± 13.0958.74 ± 12.6060.57 ± 13.550.221
Female sex, n (%)258 (74.78%)216 (75.00%)42 (73.68%)0.834
BMI, kg/m230.20 ± 5.5330.61 ± 5.5228.26 ± 5.18<0.001
ASA III-V, n (%)281 (58.79%)230 (57.64%)51 (64.56%)0.254
Operative approach, n (%)   0.648
Laparoscopic, n (%)467 (92.66%)388 (93.05%)79 (90.80%) 
Robotic, n (%)36 (7.14%)28 (6.71%)8 (9.20%) 
Thoracoscopic, n (%)1 (0.20%)1 (0.24%)0 (0%) 
Fundoplication performed, n (%)342 (68.40%)274 (66.34%)68 (78.16%)0.031
Nissen, n (%)178 (35.67%)170 (41.6%)8 (9.30%)<0.001
Toupet, n (%)144 (28.86%)95 (23.00%)49 (56.98%)<0.001
Dor, n (%)19 (3.81%)9 (2.18%)10 (11.63%)<0.001
None, n (%)158 (31.66%)139 (33.66%)19 (22.09%)<0.001
Mesh use, n (%)123 (24.50%)107 (25.78%)16 (18.39%)0.145
Collis gastroplasty, n (%)2 (0.40%)1 (0.24%)1 (1.16%)0.314
Any concomitant procedure, n (%)125 (25.46%)102 (25.12%)23 (27.06%)0.710
GERD >30 days postop, n (%)37 (7.31%)31 (7.40%)6 (6.90%)0.870
Dysphagia >30 days postop, n (%)65 (12.82%)49 (11.69%)16 (18.18%)0.098

Values are presented as mean ± SD or number (percentage), as appropriate.

Type of intervention for dysphagia
Type of intervention for dysphagiaOverall (N =29)No IEM (N =21)IEM (N = 8)P=0.203
EGD with dilation11 (37.93%)7 (33.33%)4 (50.00%) 
EGD with botulinum toxin injection1 (3.45%)0 (0.00%)1 (12.50%) 
PPI Therapy7 (24.14%)
5 (23.81%)
2 (25.00%) 
Other10 (34.38%)9 (42.86%)
1 (12.50%) 

Back to 2026 Abstracts